

Wissenschaftliche Publikationen 2012

Originalarbeiten

Erstautorenschaften

Altorjai G, Fotina I, Lütgendorf-Caucig C, Stock M, Pötter R, Georg D, Dieckmann K.
Cone-beam CT-based delineation of stereotactic lung targets: the influence of image modality and target size on interobserver variability.
Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):e265-72.

Dörr W, Herskind C.
Radiation biology of normal tissues. Scientific progress and perspectives.
Strahlenther Onkol. 2012 Nov;188 Suppl 3:295-8.

Fotina I, Lütgendorf-Caucig C, Stock M, Pötter R, Georg D.
Critical discussion of evaluation parameters for inter-observer variability in target definition for radiation therapy.
Strahlenther Onkol. 2012 Feb;188(2):160-7.

Fotina I, Hopfgartner J, Stock M, Steininger T, Lütgendorf-Caucig C, Georg D.
Feasibility of CBCT-based dose calculation: comparative analysis of HU adjustment techniques.
Radiother Oncol. 2012 Aug;104(2):249-56.

Fuchs H, Strobele J, Schreiner T, Hirtl A, Georg D.
A pencil beam algorithm for helium ion beam therapy.
Med Phys. 2012 Nov;39(11):6726-37.

Knäusl B, Hirtl A, Dobrozemsky G, Bergmann H, Kletter K, Dudczak R, Georg D.
PET based volume segmentation with emphasis on the iterative TrueX algorithm.
Z Med Phys. 2012 Feb;22(1):29-39.

Georg P, Pötter R, Georg D, Lang S, Dimopoulos JC, Sturdza AE, Berger D, Kirisits C, Dörr W.
Dose effect relationship for late side effects of the rectum and urinary bladder in magnetic resonance image-guided adaptive cervix cancer brachytherapy.
Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):653-7.

Goldner G, Pötter R, Battermann JJ, Kirisits C, Schmid MP, Slijvic S, van Vulpen M.
Comparison between external beam radiotherapy (70 Gy/74 Gy) and permanent interstitial brachytherapy in 890 intermediate risk prostate cancer patients.
Radiother Oncol. 2012 May;103(2):223-7.

Goldner G, Pötter R, Battermann JJ, Schmid MP, Kirisits C, Slijvic S, van Vulpen M.
Comparison of seed brachytherapy or external beam radiotherapy (70 Gy or 74 Gy) in 919 low-risk prostate cancer patients.
Strahlenther Onkol. 2012 Apr;188(4):305-10.

Hebar A, Rütgen BC, Selzer E.
NVX-412, a new oncology drug candidate, induces S-phase arrest and DNA damage in cancer cells in a p53-independent manner.
PLoS One. 2012;7(9):e45015.

Herrmann H, Blatt K, Ghanim V, Kneidinger M, Marth K, Valenta R, Valent P.
Glucocorticosteroids rescue basophils from dasatinib-augmented immunoglobulin E-mediated histamine release.
Int Arch Allergy Immunol. 2012;159(1):15-22.

Kauer-Dorner D, Pötter R, Resch A, Handl-Zeller L, Kirchheiner K, Meyer-Schell K, Dörr W.
Partial breast irradiation for locally recurrent breast cancer within a second breast conserving treatment: alternative to mastectomy? Results from a prospective trial.
Radiother Oncol. 2012 Jan;102(1):96-101.

Kirchheiner K, Nout R, Lindegaard J, Petrič P, Limbergen EV, Jürgenliemk-Schulz IM, Haie-Meder C, Pötter R, Dörr W.

Do clinicians and patients agree regarding symptoms? A comparison after definitive radiochemotherapy in 223 uterine cervical cancer patients.
Strahlenther Onkol. 2012 Oct;188(10):933-9.

Kirchheiner K, Fidarova E, Nout RA, Schmid MP, Sturdza A, Wiebe E, Kranz A, Polterauer S, Pötter R, Dörr W.

Radiation-induced morphological changes in the vagina.
Strahlenther Onkol. 2012 Nov;188(11):1010-7.

Kuess P, Birkfellner W, Enghardt W, Helmbrecht S, Fiedler F, Georg D.

Using statistical measures for automated comparison of in-beam PET data.
Med Phys. 2012 Oct;39(10):5874-81.

Lütgendorf-Caucig C, Fotina I, Gallop-Evans E, Claude L, Lindh J, Pelz T, Knäusl B, Georg D, Pötter R, Dieckmann K; EuroNet-PHL RT Group.

Multicenter evaluation of different target volume delineation concepts in pediatric Hodgkin's lymphoma. A case study.
Strahlenther Onkol. 2012 Nov;188(11):1025-30.

Nesvacil N, Lueftinger T, Shulyak D, Obbrugger M, Weiss W, Drake NA, Hubrig S, Ryabchikova T, Kochukhov O, Piskunov N, Polosukhina N.

Multi-element Doppler imaging of the CP2 star HD 3980.
Astronomy and Astrophysics - Les Ulis 2012 537:A151

Pötter R, Eriksen JG, Beavis AW, Coffey M, Verfaillie C, Leer JW, Valentini V.

Competencies in radiation oncology: a new approach for education and training of professionals for Radiotherapy and Oncology in Europe.
Radiother Oncol. 2012 Apr;103(1):1-4.

Schmid MP, Pötter R, Bombosch V, Slijivic S, Kirisits C, Dörr W, Goldner G.

Late gastrointestinal and urogenital side-effects after radiotherapy—incidence and prevalence. Subgroup-analysis within the prospective Austrian-German phase II multicenter trial for localized prostate cancer.
Radiother Oncol. 2012 Jul;104(1):114-8.

Selzer E, Hebar A.

Basic principles of molecular effects of irradiation.
Wien Med Wochenschr. 2012 Feb;162(3-4):47-54.

Selzer E, Hebar A.

[Biological effect and tumor risk of diagnostic x-rays. The "war of the theories"].
Radiologe. 2012 Oct;52(10):892-7.

Simmat I, Georg P, Georg D, Birkfellner W, Goldner G, Stock M.

Assessment of accuracy and efficiency of atlas-based autosegmentation for prostate radiotherapy in a variety of clinical conditions.
Strahlenther Onkol. 2012 Sep;188(9):807-15.

Stock M, Palm A, Altendorfer A, Steiner E, Georg D.

IGRT induced dose burden for a variety of imaging protocols at two different anatomical sites.
Radiother Oncol. 2012 Mar;102(3):355-63.

Ströbele J, Schreiner T, Fuchs H, Georg D.

Comparison of basic features of proton and helium ion pencil beams in water using GATE.
Z Med Phys. 2012 Sep;22(3):170-8.

Koautorenschaften

Bartsch R, Berghoff A, Pluschnig U, Bago-Horvath Z, Dubsky P, Rottenfusser A, DeVries C, Rudas M, Fitzal F, Dieckmann K, Mader RM, Gnant M, Zielinski CC, Steger GG.

Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases.

Br J Cancer. 2012 Jan 3;106(1):25-31.

Bartsch R, Bago-Horvath Z, Berghoff A, DeVries C, Pluschnig U, Dubsky P, Rudas M, Mader RM, Rottenfusser A, Fitzal F, Gnant M, Zielinski CC, Steger GG.

Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer.

Eur J Cancer. 2012 Sep;48(13):1932-8.

Bentzen SM, Dörr W, Gahbauer R, Howell RW, Joiner MC, Jones B, Jones DT, van der Kogel AJ, Wambersie A, Whitmore G.

Bioeffect modeling and equieffective dose concepts in radiation oncology - Terminology, quantities and units.

Radiother Oncol. 2012 Nov;105(2):266-8.

Berghoff A, Bago-Horvath Z, De Vries C, Dubsky P, Pluschnig U, Rudas M, Rottenfusser A, Knauer M, Eiter H, Fitzal F, Dieckmann K, Mader RM, Gnant M, Zielinski CC, Steger GG, Preusser M, Bartsch R.

Brain metastases free survival differs between breast cancer subtypes.

Br J Cancer. 2012 Jan 31;106(3):440-6.

Berghoff AS, Bago-Horvath Z, Ilhan-Mutlu A, Magerle M, Dieckmann K, Marosi C, Birner P, Widhalm G, Steger GG, Zielinski CC, Bartsch R, Preusser M.

Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors.

Br J Cancer. 2012 Oct 23;107(9):1454-8.

Beyreuther E, Dörr W, Lehnert A, Lessmann E, Pawelke J.

FISH-based analysis of 10- and 25-kV soft X-ray-induced DNA damage in 184A1 human mammary epithelial cells.

Radiat Environ Biophys. 2012 Mar;51(1):33-42.

Blatt K, Herrmann H, Mirkina I, Hadzijusufovic E, Peter B, Strommer S, Hoermann G, Mayerhofer M, Hoetzenecker K, Klepetko W, Ghanim V, Marth K, Füreder T, Wacheck V, Valenta R, Valent P.

The PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophils.

PLoS One. 2012;7(1):e29925.

Combs SE, Kieser M, Habermehl D, Weitz J, Jäger D, Fossati P, Orrechia R, Engenhart-Cabillic R, Pötter R, Dosanjh M, Jäkel O, Büchler MW, Debus J.

Phase I/II trial evaluating carbon ion radiotherapy for the treatment of recurrent rectal cancer: the PANDORA-01 trial.

BMC Cancer. 2012 Apr 3;12:137.

Dunavoelgyi R, Dieckmann K, Gleiss A, Sacu S, Kircher K, Georgopoulos M, Georg D, Zehetmayer M, Poetter R.

Radiogenic side effects after hypofractionated stereotactic photon radiotherapy of choroidal melanoma in 212 patients treated between 1997 and 2007.

Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):121-8.

Eriksen JG, Beavis AW, Coffey MA, Leer JW, Magrini SM, Benstead K, Boelling T, Hjälms-Eriksson M, Kantor G, Maciejewski B, Mezeckis M, Oliveira A, Thirion P, Vitek P, Olsen DR, Eudaldo T, Enghardt W, François P, Garibaldi C, Heijmen B, Josipovic M, Major T, Nikolettopoulos S, Rijnders A, Waligorski M, Wasilewska-Radwanska M, Mullaney L, Boejen A, Vaandering A, Vandevelde G, Verfaillie C, Pötter R.

The updated ESTRO core curricula 2011 for clinicians, medical physicists and RTTs in radiotherapy/radiation oncology.

Radiother Oncol. 2012 Apr;103(1):103-8.

Flechl B, Ackerl M, Sax C, Dieckmann K, Crevenna R, Gaiger A, Widhalm G, Preusser M, Marosi C. Neurocognitive and sociodemographic functioning of glioblastoma long-term survivors.

J Neurooncol. 2012 Sep;109(2):331-9.

Gendrin C, Furtado H, Weber C, Bloch C, Figl M, Pawiro SA, Bergmann H, Stock M, Fichtinger G, Georg D, Birkfellner W.

Monitoring tumor motion by real time 2D/3D registration during radiotherapy.

Radiother Oncol. 2012 Feb;102(2):274-80.

Grabner G, Nöbauer I, Elandt K, Kronnerwetter C, Woehrer A, Marosi C, Prayer D, Trattng S, Preusser M.

Longitudinal brain imaging of five malignant glioma patients treated with bevacizumab using susceptibility-weighted magnetic resonance imaging at 7 T.

Magn Reson Imaging. 2012 Jan;30(1):139-47.

Helmbrecht S, Santiago A, Enghardt W, Kuess P, Fiedler F.

On the feasibility of automatic detection of range deviations from in-beam PET data.

Phys Med Biol. 2012 Mar 7;57(5):1387-97.

Herrmann H, Cerny-Reiterer S, Gleixner KV, Blatt K, Herndlhofer S, Rabitsch W, Jäger E, Mitterbauer-Hohendanner G, Streubel B, Selzer E, Schwarzingger I, Sperr WR, Valent P.

CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin.

Haematologica. 2012 Feb;97(2):219-26.

Keilani M, Krall C, Marosi C, Flechl B, Dieckmann K, Widhalm G, Marhold M, Crevenna R.

Strength of skeletal muscle and self-reported physical performance in Austrian glioblastoma-patients.

Wien Klin Wochenschr. 2012 Jun;124(11-12):377-83.

Kessel KA, Bougatf N, Bohn C, Habermehl D, Oetzel D, Bendl R, Engelmann U, Orecchia R, Fossati P, Pötter R, Dosanjh M, Debus J, Combs SE.

Connection of European particle therapy centers and generation of a common particle database system within the European ULICE-framework.

Radiat Oncol. 2012 Jul 24;7:115.

Lagler H, Tobudic S, Ramharter M, Elandt K, Sperr WR, Redlberger-Fritz M, Popow-Kraupp T, Jäger U, Zielinski CC, Burgmann H.

Pandemic whole-virion, Vero-cell-derived, adjuvant-free influenza A H1N1 vaccine in patients with solid tumors and hematologic malignancies receiving concurrent anticancer treatment: Immunogenicity, tolerability, and acceptability during the pandemic situation.

Vaccine. 2012 Nov 6;30(48):6864-70.

Lohr F, Baus W, Vorwerk H, Schlömp B, André L, Georg D, Hodapp N; AG Patientensicherheit der DEGRO/DGMP/VMTRO sowie für die ÖGRO/ÖGMP und SASRO/SGSMP.

[Rules and regulations applying to incidents in radiotherapy].

Strahlenther Onkol. 2012 Jul;188(7):545-50.

Penjweini R, Loew HG, Hamblin MR, Kratky KW.

Long-term monitoring of live cell proliferation in presence of PVP-Hypericin: a new strategy using ms pulses of LED and the fluorescent dye CFSE.

J Microsc. 2012 Jan;245(1):100-8.

Peyrl A, Chocholous M, Kieran MW, Azizi AA, Prucker C, Czech T, Dieckmann K, Schmook MT, Haberler C, Leiss U, Slavic I.

Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors.

Pediatr Blood Cancer. 2012 Sep;59(3):511-7.

Poeschl PW, Seemann R, Czembirek C, Russmueller G, Sulzbacher I, Selzer E, Nuhic D, Ewers R. Impact of elective neck dissection on regional recurrence and survival in cN0 staged oral maxillary squamous cell carcinoma.

Oral Oncol. 2012 Feb;48(2):173-8.

Pohl G, Marosi C, Dieckmann K, Goldner G, Elandt K, Hassler M, Schemper M, Strasser-Weippl K, Nauck F, Gaertner J, Watzke H.

Evaluation of diagnostic and treatment approaches towards acute dyspnea in a palliative care setting among medical students at the University of Vienna.

Wien Med Wochenschr. 2012 Jan;162(1-2):18-28.

Plass CA, Loew HG, Podesser BK, Prusa AM.

Light-induced vasodilation of coronary arteries and its possible clinical implication.

Ann Thorac Surg. 2012 Apr;93(4):1181-6.

Polterauer S, Grimm C, Hofstetter G, Concini N, Natter C, Sturdza A, Pötter R, Marth C, Reinthaller A, Heinze G.

Nomogram prediction for overall survival of patients diagnosed with cervical cancer.

Br J Cancer. 2012 Sep 4;107(6):918-24.

Preusser M, Seywald S, Elandt K, Kurz C, Rottenfusser A, Dieckmann K, Altorjai G, Zielinski CC, Marosi C.

Pilot study on sex hormone levels and fertility in women with malignant gliomas.

J Neurooncol. 2012 Apr;107(2):387-94.

Preusser M, Spiegl-Kreinecker S, Lötsch D, Wöhrer A, Schmook M, Dieckmann K, Saringer W, Marosi C, Berger W.

Trabectedin has promising antineoplastic activity in high-grade meningioma.

Cancer. 2012 Oct 15;118(20):5038-49.

Siller-Matula JM, Miller I, Gemeiner M, Plasenzotti R, Bayer G, Mesteri I, Fabry A, Petroczi K, Nöbauer K, Razzazi-Fazeli E, Planchon S, Renaut J, Quehenberger P, Selzer E, Jilka B.

Continuous thrombin infusion leads to a bleeding phenotype in sheep.

Thromb Res. 2012 Aug;130(2):226-36.

Spoerk J, Gendrin C, Weber C, Figl M, Pawiro SA, Furtado H, Fabri D, Bloch C, Bergmann H, Gröller E, Birkfellner W.

High-performance GPU-based rendering for real-time, rigid 2D/3D-image registration and motion prediction in radiation oncology.

Z Med Phys. 2012 Feb;22(1):13-20.

Viswanathan AN, Beriwal S, De Los Santos JF, Demanes DJ, Gaffney D, Hansen J, Jones E, Kirisits C, Thomadsen B, Erickson B; American Brachytherapy Society.

American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II: high-dose-rate brachytherapy.

Brachytherapy. 2012 Jan-Feb;11(1):47-52.

Wicklein D, Ramos Leal N, Salamon J, Thamer M, Herrmann H, Valent P, Schumacher U, Ullrich S. Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft model.

PLoS One. 2012;7(2):e30567.